이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

궤양 성 대장염 환자에서 SAR441566의 효능 및 안전성을 조사하는 연구 (SPECIFI-UC)

2026년 10월 16일 업데이트: Sanofi

2 단계, 다국적, 다기관, 무작위, 이중 맹검, 위약 대조, 용량 범위 연구, 중등도에서 검증 된 궤양 성 대장염이있는 성인의 SAR441566의 효능 및 안전성을 평가하기위한 복용량 범위 연구

This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis.

This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment.

Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study).

  • The study duration will be up to 59 weeks.
  • The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm.
  • The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.

연구 개요

상태

종료됨

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

170

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Tbilisi, 그루지야, 0160
        • Investigational Site Number : 2680003
      • Tbilisi, 그루지야, 0144
        • Investigational Site Number : 2680002
      • Tbilisi, 그루지야, 0180
        • Investigational Site Number : 2680001
      • Athens, 그리스, 124 62
        • Investigational Site Number : 3000003
      • Athens, 그리스, 106 76
        • Investigational Site Number : 3000001
      • Heraklion, 그리스, 711 10
        • Investigational Site Number : 3000002
      • Cape Town, 남아프리카, 7405
        • Investigational Site Number : 7100002
      • Cape Town, 남아프리카, 7708
        • Investigational Site Number : 7100001
      • KwaDukuza, 남아프리카, 4449
        • Investigational Site Number : 7100004
      • Pretoria, 남아프리카, 0157
        • Investigational Site Number : 7100005
      • Pretoria, 남아프리카, 0002
        • Investigational Site Number : 7100003
      • Berlin, 독일, 10117
        • Investigational Site Number : 2760005
      • Berlin, 독일, 14050
        • Investigational Site Number : 2760008
      • Duisburg, 독일, 47055
        • Investigational Site Number : 2760010
      • Frankfurt, 독일, 60590
        • Investigational Site Number : 2760009
      • Hanover, 독일, 30625
        • Investigational Site Number : 2760003
      • Tübingen, 독일, 72076
        • Investigational Site Number : 2760011
      • Ulm, 독일, 89081
        • Investigational Site Number : 2760006
      • Constanța, 루마니아, 900673
        • Investigational Site Number : 6420001
    • Arizona
      • Sun City, Arizona, 미국, 85351
        • GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400003
    • Connecticut
      • Bristol, Connecticut, 미국, 06010
        • Bristol Hospital- Site Number : 8400017
    • Florida
      • Clermont, Florida, 미국, 34711
        • Novum Research- Site Number : 8400018
      • Kissimmee, Florida, 미국, 34741
        • Clinical Research of Osceola- Site Number : 8400012
      • Miami Lakes, Florida, 미국, 33016
        • Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400002
      • Tampa, Florida, 미국, 33609
        • GCP Clinical Research- Site Number : 8400016
    • Illinois
      • Glenview, Illinois, 미국, 60026
        • GI Alliance - Glenview- Site Number : 8400005
      • Gurnee, Illinois, 미국, 60031
        • Illinois Gastroenterology Group- Site Number : 8400004
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • University of Michigan Health System - Ann Arbor- Site Number : 8400010
    • New York
      • New York, New York, 미국, 10029
        • Icahn School of Medicine at Mount Sinai- Site Number : 8400001
      • Queens Village, New York, 미국, 11428
        • Queens Village Primary Medical Center- Site Number : 8400011
    • Ohio
      • Lima, Ohio, 미국, 45805
        • NexGen Research- Site Number : 8400020
    • Pennsylvania
      • Uniontown, Pennsylvania, 미국, 15401
        • Frontier Clinical Research - Uniontown- Site Number : 8400006
    • South Carolina
      • Charleston, South Carolina, 미국, 29401
        • Medical University Of South Carolina - MUSC Health Ashley River Tower - ART- Site Number : 8400008
    • Texas
      • Katy, Texas, 미국, 77494
        • Gastro Health & Nutrition- Site Number : 8400007
      • Lubbock, Texas, 미국, 79424
        • SI Research Associates- Site Number : 8400019
      • Southlake, Texas, 미국, 76092
        • Texas Digestive Disease Consultants - Southlake- Site Number : 8400015
    • Washington
      • Seattle, Washington, 미국, 98195
        • University of Washington Medical Center- Site Number : 8400014
      • Tacoma, Washington, 미국, 98405
        • Washington Gastroenterology - Tacoma- Site Number : 8400009
      • Ghent, 벨기에, 9000
        • Investigational Site Number : 0560002
      • Leuven, 벨기에, 3000
        • Investigational Site Number : 0560001
      • Burgas, 불가리아, 8000
        • Investigational Site Number : 1000001
      • Rousse, 불가리아, 7002
        • Investigational Site Number : 1000003
      • Sofia, 불가리아, 1612
        • Investigational Site Number : 1000002
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, 브라질, 90035903
        • Hospital de Clinicas de Porto Alegre- Site Number : 0760002
      • Porto Alegre, Rio Grande do Sul, 브라질, 90160-093
        • Hospital Ernesto Dornelles- Site Number : 0760003
      • Buenos Aires, 아르헨티나, 1061
        • Investigational Site Number : 0320001
      • Buenos Aires, 아르헨티나, 1006
        • Investigational Site Number : 0320003
      • Buenos Aires, 아르헨티나, 1023
        • Investigational Site Number : 0320002
      • Buenos Aires, 아르헨티나, 1125
        • Investigational Site Number : 0320005
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, 아르헨티나, 4000
        • Investigational Site Number : 0320004
      • Salzburg, 오스트리아, 5020
        • Investigational Site Number : 0400002
      • Vienna, 오스트리아, 1090
        • Investigational Site Number : 0400001
      • Alessandria, 이탈리아, 15100
        • Investigational Site Number : 3800007
      • Palermo, 이탈리아, 90127
        • Investigational Site Number : 3800009
      • Pisa, 이탈리아, 56124
        • Investigational Site Number : 3800004
    • Genova
      • Genoa, Genova, 이탈리아, 16132
        • Investigational Site Number : 3800006
    • Milano
      • Milan, Milano, 이탈리아, 20132
        • Investigational Site Number : 3800002
      • Rozzano, Milano, 이탈리아, 20089
        • Investigational Site Number : 3800003
    • Napoli
      • Naples, Napoli, 이탈리아, 80131
        • Investigational Site Number : 3800008
    • Padova
      • Padua, Padova, 이탈리아, 35128
        • Investigational Site Number : 3800001
    • Roma
      • Rome, Roma, 이탈리아, 00161
        • Investigational Site Number : 3800011
    • Torino
      • Turin, Torino, 이탈리아, 10126
        • Investigational Site Number : 3800010
      • Hyderabad, 인도, 500082
        • Investigational Site Number : 3560005
      • Jaipur, 인도, 302001
        • Investigational Site Number : 3560003
      • Jaipur, 인도, 302004
        • Investigational Site Number : 3560009
      • Kolkata, 인도, 700020
        • Investigational Site Number : 3560002
      • Ludhiana, 인도, 141002
        • Investigational Site Number : 3560004
      • Secunderabad, 인도, 500003
        • Investigational Site Number : 3560007
      • Surat, 인도, 395002
        • Investigational Site Number : 3560001
      • Visakhapatnam, 인도, 530040
        • Investigational Site Number : 3560010
      • Hiroshima, 일본, 734-8530
        • Investigational Site Number : 3920012
      • Kagoshima, 일본, 892-0843
        • Investigational Site Number : 3920016
      • Niigata, 일본, 950-1104
        • Investigational Site Number : 3920001
      • Osaka, 일본, 530-0011
        • Investigational Site Number : 3920010
      • Tokyo, 일본, 108-8642
        • Investigational Site Number : 3920015
    • Chiba
      • Kashiwa, Chiba, 일본, 277-0871
        • Investigational Site Number : 3920005
    • Hiroshima
      • Kure, Hiroshima, 일본, 737-0811
        • Investigational Site Number : 3920014
    • Hokkaido
      • Sapporo, Hokkaido, 일본, 004-0041
        • Investigational Site Number : 3920003
      • Sapporo, Hokkaido, 일본, 065-0033
        • Investigational Site Number : 3920007
    • Iwate
      • Yahaba, Iwate, 일본, 028-3695
        • Investigational Site Number : 3920009
    • Kanagawa
      • Yokohama, Kanagawa, 일본, 220-0041
        • Investigational Site Number : 3920013
    • Tokyo
      • Bunkyo-Ku, Tokyo, 일본, 113-8510
        • Investigational Site Number : 3920002
      • Kodaira, Tokyo, 일본, 187-8510
        • Investigational Site Number : 3920011
    • Yamanashi
      • Kofu, Yamanashi, 일본, 400-0027
        • Investigational Site Number : 3920006
      • Guangzhou, 중국, 510655
        • Investigational Site Number : 1560002
      • Hangzhou, 중국, 310016
        • Investigational Site Number : 1560001
      • Huizhou, 중국, 516001
        • Investigational Site Number : 1560003
      • Huizhou, 중국, 516001
        • Investigational Site Number : 1560017
      • Jiazhuang, 중국, 050000
        • Investigational Site Number : 1560004
      • Linhai, 중국, 317000
        • Investigational Site Number : 1560014
      • Luoyang, 중국, 471003
        • Investigational Site Number : 1560008
      • Shanghai, 중국, 200120
        • Investigational Site Number : 1560005
      • Wuhan, 중국, 430014
        • Investigational Site Number : 1560011
      • Olomouc, 체코, 779 00
        • Investigational Site Number : 2030001
      • Ostrava, 체코, 710 00
        • Investigational Site Number : 2030002
    • Reg Metropolitana de Santiago
      • Santiago, Reg Metropolitana de Santiago, 칠레, 8330034
        • Investigational Site Number : 1520003
      • Santiago, Reg Metropolitana de Santiago, 칠레, 7500010
        • Investigational Site Number : 1520002
      • Santiago, Reg Metropolitana de Santiago, 칠레, 8331143
        • Investigational Site Number : 1520001
    • Nova Scotia
      • Kentville, Nova Scotia, 캐나다, B4N 0A3
        • Investigational Site Number : 1240004
    • Ontario
      • Ajax, Ontario, 캐나다, L1S 7K7
        • Investigational Site Number : 1240006
      • Richmond Hill, Ontario, 캐나다, L4C 9M7
        • Investigational Site Number : 1240005
    • Quebec
      • Québec, Quebec, 캐나다, G1N 4V3
        • Investigational Site Number : 1240001
      • Osijek, 크로아티아, 31000
        • Investigational Site Number : 1910001
      • Istanbul, 터키 (Türkiye), 34899
        • Investigational Site Number : 7920002
      • Izmir, 터키 (Türkiye), 35100
        • Investigational Site Number : 7920003
      • Mersin, 터키 (Türkiye), 33070
        • Investigational Site Number : 7920001
    • Lesser Poland Voivodeship
      • Oświęcim, Lesser Poland Voivodeship, 폴란드, 32-600
        • Investigational Site Number : 6160008
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, 폴란드, 53-034
        • Investigational Site Number : 6160005
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 03-580
        • Investigational Site Number : 6160004
      • Warsaw, Masovian Voivodeship, 폴란드, 04-501
        • Investigational Site Number : 6160001
    • Podkarpackie Voivodeship
      • Rzeszów, Podkarpackie Voivodeship, 폴란드, 35-055
        • Investigational Site Number : 6160002
      • Nice, 프랑스, 06202
        • Investigational Site Number : 2500003
      • Toulouse, 프랑스, 31059
        • Investigational Site Number : 2500001
      • Vandœuvre-lès-Nancy, 프랑스, 54511
        • Investigational Site Number : 2500002
      • Budapest, 헝가리
        • Investigational Site Number : 3480001
    • South Australia
      • Kurralta Park, South Australia, 호주, 5037
        • Investigational Site Number : 0360003
    • Victoria
      • Richmond, Victoria, 호주, 3121
        • Investigational Site Number : 0360005

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Male or female participants aged 18 to 75 years inclusive, at the time of signing the informed consent

  • Participants who have clinical evidence of active UC for ≥3 months before screening and confirmed by endoscopy during the screening period

  • Active moderate-to-severe UC at screening as defined by a modified Mayo Score (mMS) of 5 to 9 (without the Physician global Assessment (PGA), with a minimum rectal bleeding (RB) subscore ≥1, a minimum stool frequency (SF) subscore ≥1, a mMES ≥2 confirmed by central reader, a minimum sum of all subscores of 5, and a disease extent >15 cm from the anal verge

  • Must have received prior treatment for UC (either "a" or "b" below or a combination of both "a" and "b"):

    1. History of no prior exposure to approved Advanced Therapy (AT), but having inadequate response to, loss of response to or intolerance to standard treatment with any of the following : 5-ASA, thiopurines (eg.6-MP, AZA), MTX, oral or intravenous (IV) corticosteroids or history of corticosteroid dependence (defined an inability to successfully taper corticosteroids without recurrence of UC) OR
    2. History of inadequate response to, loss of response to or intolerance to treatment with ≥1 approved AT such as a biologic agent (eg. TNF antagonists, anti-integrin other than natalizumab, anti-IL-12/23, anti-IL-23, or a small molecule (such as a JAKi or S1PRm) for UC
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participants with active CD, indeterminate colitis, ischemic colitis, microscopic colitis
  • Participants with the following ongoing known complications of UC: fulminant colitis, toxic megacolon, or any other manifestation that might require bowel surgery while enrolled in the study
  • Participant with prior colectomy, ostomy or ileoanal pouch, or anticipated colectomy during their participation in the study
  • Participants with fecal sample positive for ova or parasites, bacterial pathogens, or positive for Clostridium difficile B toxin in stools
  • Participants with active tuberculosis (TB) or a history of incompletely treated active TB or latent TB infection per local guidelines
  • Participants with Positive Hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) and/or hepatitis C virus antibody (HCVAb) at the screening visit
  • Participants with any other active, chronic or recurrent infection, including recurrent or disseminated herpes zoster or disseminated herpes simplex
  • Participants with a known history of human immunodeficiency virus (HIV) infection or positive HIV-1 or HIV-2 serology at screening
  • Participants presenting with active malignancies, lymphoproliferative disease, or recurrence of either, within the 5 years before screening
  • History of gastro-intestinal dysplasia other than completely removed low grade dysplasia OR presence of colonic mucosal dysplasia or adenomatous colonic polyps not removed during endoscopy by the time of the screening visit.
  • If the participant has extensive colitis for ≥8 years or disease limited to left side of colon (ie, distal to splenic flexure) for >10 years, regardless of age, a colonoscopy within 1 year of the screening visit is required to survey for dysplasia. Participants with dysplasia or cancer identified on biopsies will be excluded.
  • Female participants who is pregnant, breastfeeding, or is considering becoming pregnant during the study or within 3 months after the last dose of study drug
  • Infection(s) requiring treatment with IV anti-infectives within 30 days prior to the screening visit or oral/intramuscular anti-infectives within 14 days prior to the screening visit
  • Participants requiring or receiving any parental nutrition and/or exclusive enteral nutrition
  • Participants who received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to screening
  • Participants who received fecal microbial transplantation within 30 days prior to screening
  • Participants who have ever been exposed to natalizumab (Tysabri®) or oral carotegrast methyl (Carogra®)
  • Participants who received IV corticosteroids within 14 days prior to screening or during screening period
  • Screening laboratory and other analyses show abnormal results.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: SAR441566 dose regimen 1

Participants will receive SAR441566 dose regimen 1

Pharmaceutical form: Tablet Route of administration: Oral

실험적: SAR441566 dose regimen 2

Participants will receive SAR441566 dose regimen 2

Pharmaceutical form: Tablet Route of administration: Oral

실험적: SAR441566 dose regimen 3

Participants will receive SAR441566 dose regimen 3

Pharmaceutical form: Tablet Route of administration: Oral

위약 비교기: Placebo

Participants will receive SAR441566-matching placebo

Pharmaceutical form: Tablet Route of administration: Oral

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of participants achieving clinical remission at Week 12 by modified Mayo Score (mMS)
기간: Week 12

Clinical remission by modified Mayo score (mMS) is defined as a mMS ≤2 with no subscore >1 (stool frequency [SF] of 0 or 1 with at least a 1-point decrease from baseline, rectal bleeding [RB] of 0 and modified Mayo Endoscopic Subscore [mMES] of 0 or 1 where 1 does not include friability).

Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity.

Week 12

2차 결과 측정

결과 측정
측정값 설명
기간
선택된 방문시 SAR441566의 혈장 프리즈 농도
기간: 최대 52 주
최대 52 주
선택된 방문시 SAR441566의 혈장 후 농도
기간: 최대 52 주
최대 52 주
유도 및 유지 치료 기간 동안 치료 응급 부작용 (TEAES)이있는 참가자 수
기간: 최대 52 주
최대 52 주
오픈 라벨 치료 기간 동안 치료 응급 부작용 (TEAES)이있는 참가자 수
기간: 12 주에서 주 52 주차
12 주에서 주 52 주차
Proportion of participants achieving clinical response at Week 12 by modified Mayo Score (mMS)
기간: Week 12

Clinical response by modified Mayo score (mMS) is defined as a decrease from baseline in the mMS of ≥2 points and an improvement of ≥30% from baseline plus a decrease in rectal bleeding (RB) subscore ≥1 or an absolute RB subscore ≤1.

Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity.

Week 12
Proportion of participants achieving clinical response at Week 12 by full Mayo score (MS)
기간: Week 12

Clinical response by full Mayo score (MS) is defined as a decrease from baseline in the MS of ≥3 points and an improvement of ≥30% from baseline plus a decrease in rectal bleeding (RB) subscore ≥1 or an absolute RB subscore ≤1.

The MS (also referred to as the full Mayo Score) is a composite index designed to measure ulcerative colitis (UC) disease activity and consists of 4 subscores: RB and SF, which are patient-reported subscores, Physician's global assessment (PGA), and endoscopic findings. Individual items are rated 0 to 3, giving the composite score a maximum of 12, with higher scores indicating greater disease severity.

Week 12
Proportion of participants achieving clinical remission at Week 12 by full Mayo score (MS)
기간: Week 12

Clinical remission by full Mayo score (MS) is defined as a MS ≤2 with no score >1.

Week 12
Proportion of participants achieving the combination of patient-reported outcome 2 (PRO2) remission and endoscopic remission at Week 12
기간: Week 12

Patient-reported outcome 2 (PRO2) remission is defined as PRO2 score ≤1 with rectal bleeding (RB) of 0, and endoscopic remission is defined as mMES of 0.

PRO2 score is defined as the sum of Mayo SF and RB subscores.

Week 12
Proportion of participants achieving endoscopic remission at Week 12
기간: Week 12

Endoscopic remission is defined as mMES of 0.

Week 12
Change from baseline in PRO2 from randomization to Week 12
기간: From Baseline to Week 12

PRO2 score is defined as the sum of the Mayo SF and RB subscores.

From Baseline to Week 12
Proportion of participants achieving endoscopic response at Week 12
기간: Week 12

Endoscopic response is defined as mMES decrease of at least 1 point.

Week 12
Proportion of participants achieving endoscopic improvement at Week 12
기간: Week 12

Endoscopic improvement is defined as mMES of 0 or 1 where 1 does not include friability.

Week 12
Proportion of participants achieving HEMI at Week 12
기간: Week 12

Histologic endoscopic mucosal improvement (HEMI) is defined by achievement of modified Mayo endoscopic improvement (mMES of 0 or 1 where 1 does not include friability) and histological improvement (original Geboes Score [OGS] ≤3.1).

Week 12
Proportion achieving Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 12
기간: Week 12

Inflammatory Bowel Disease Questionnaire (IBDQ) remission is considered as an IBDQ-32 total score ≥170 points.

IBDQ is designed to capture the patient's experience of IBD on 4 domains of functioning and well-being: bowel and systemic symptoms and emotional and social function. The total IBDQ score ranges from 32 to 224 which indicates better quality of life.

Week 12
Proportion of participants achieving Inflammatory Bowel Disease Questionnaire (IBDQ) response at Week 12
기간: Week 12

Inflammatory Bowel Disease Questionnaire (IBDQ) response is defined as an increase from baseline in the total IBDQ score in the range of 16 to 32 points.

Week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 3월 28일

기본 완료 (실제)

2026년 8월 6일

연구 완료 (실제)

2026년 10월 12일

연구 등록 날짜

최초 제출

2025년 3월 4일

QC 기준을 충족하는 최초 제출

2025년 3월 4일

처음 게시됨 (실제)

2025년 3월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 16일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • DRI17822
  • U1111-1308-9729 (기타 식별자: WHO)
  • 2025-520705-12 (레지스트리 식별자: CTIS)
  • 2025 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .